Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations

Optimizing Systemic Therapy for Bladder Cancer

(2017) Sumanta K. Pal et al.   Journal of the National Comprehensive Cancer Network

Prognostic Factors in Urothelial Carcinoma of the Bladder

(2015) James P. Solomon et al.   ADVANCES IN ANATOMIC PATHOLOGY

The Role of Genomics in the Management of Advanced Bladder Cancer

(2015) Elizabeth A. Guancial et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Re: Whole-genome and Whole-exome Sequencing of Bladder Cancer Identifies Frequent Alterations in Genes Involved in Sister Chromatid Cohesion and Segregation

(2015) Eugene K. Cha et al.   EUROPEAN UROLOGY

Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation

(2015) Siraj M. Ali et al.   EUROPEAN UROLOGY

Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification

(2015) Norma Palma et al.   EUROPEAN UROLOGY

Novel molecular targets for urothelial carcinoma

(2015) Bishoy M Faltas et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review

(2015) Vishal Vashistha et al.   BMC CANCER

Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors

(2015) Lecia V. Sequist et al.   CANCER RESEARCH

Targeted therapies in urothelial carcinoma

(2014) Monalisa Ghosh et al.   CURRENT OPINION IN ONCOLOGY

Response of an ERBB2-Mutated Inflammatory Breast Carcinoma to Human Epidermal Growth Factor Receptor 2–Targeted Therapy

(2014) Siraj M. Ali et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive molecular characterization of urothelial bladder carcinoma

(2014)   NATURE

Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin

(2014) J. Chmielecki et al.   ONCOLOGIST

Treatment of Metastatic Extramammary Paget's Disease Associated With Adnexal Adenocarcinoma, With Anti-HER2 Drugs Based on Genomic Alteration ERBB2 S310F

(2014) O. Vornicova et al.   ONCOLOGIST

Molecular biomarkers for predicting outcomes in urothelial carcinoma of the bladder

(2014) Nikhil Sapre et al.   PATHOLOGY

Erratum: Corrigendum: Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden

(2014) J. -B. Cazier et al.   Nature Communications

Toward a Molecular Pathologic Classification of Urothelial Carcinoma

(2013) Gottfrid Sjödahl et al.   AMERICAN JOURNAL OF PATHOLOGY

Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis

(2013) Firas Abdollah et al.   Cancer Epidemiology

Relapsed Classic E-Cadherin (CDH1)-Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations

(2013) J. S. Ross et al.   CLINICAL CANCER RESEARCH

A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma

(2013) J. S. Ross et al.   CLINICAL CANCER RESEARCH

Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

(2013) Julien Mazières et al.   JOURNAL OF CLINICAL ONCOLOGY

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy

(2013) Jeffrey S Ross et al.   MODERN PATHOLOGY

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

(2013) Garrett M Frampton et al.   NATURE BIOTECHNOLOGY

Challenging current paradigms

(2013) Aidan P. Noon et al.   Nature Reviews Urology

Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment

(2013) Grit S. Herter-Sprie et al.   Frontiers in Oncology

Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression

(2012) Paul Chih-Hsueh Chen et al.   JOURNAL OF CLINICAL PATHOLOGY

Diagnosis and Treatment of Bladder Cancer: How Can We Improve?

(2012) Michael A. Gorin et al.   POSTGRADUATE MEDICINE

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2

(2012) H. Greulich et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

(2012) Ron Bose et al.   Cancer Discovery

Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours

(2011) Achim Fleischmann et al.   EUROPEAN UROLOGY

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

(2011) F. Janku et al.   MOLECULAR CANCER THERAPEUTICS

How to apply de Bruijn graphs to genome assembly

(2011) Phillip E C Compeau et al.   NATURE BIOTECHNOLOGY

Early Accelerated Approval for Highly Targeted Cancer Drugs

(2011) Bruce A. Chabner   NEW ENGLAND JOURNAL OF MEDICINE

Role of anti-Her-2 therapy in bladder carcinoma

(2010) Álvaro Pinto Marín et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Emerging Targeted Therapies for Breast Cancer

(2010) Ricardo H. Alvarez et al.   JOURNAL OF CLINICAL ONCOLOGY

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

(2010) S. A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Bladder cancer

(2009) Donald S Kaufman et al.   LANCET

Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications

(2009) Mahul B Amin   MODERN PATHOLOGY

Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer

(2009) Michael P. Porter et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

The present and future burden of urinary bladder cancer in the world

(2009) Martine Ploeg et al.   WORLD JOURNAL OF UROLOGY

Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

(2008) Fabio Calabrò et al.   EUROPEAN UROLOGY